AGENDA

AGENDA

FRIDAY, MARCH 24, 2023

1500-1610h Registration and CCOLD Welcome Reception- Heritage Hall
1610-1620h Welcome and Introductions – Mt Temple Ballroom 
MYELOMA SESSION
1630-1700h Multiple Myeloma Testing: New insights and Role of MRD in Clinical Practice

Dr. Paola Neri

1700-1740h Debate : Transplant or No Transplant

Dr. Philippe Moreau : Yes / Dr. Nizar Bahlis : No

1740-1810h Treatment of High Risk Myeloma – Dr. Nizar Bahlis
1810-1840h Immune Therapy for Myeloma – Dr. Philippe Moreau
1840-1920h Panel Discussion – Chair: x, Panel: Dr. Bahlis, Dr. Moreau, Dr. Neri
1930h CCOLD Opening Dinner – Victoria Ballroom

SATURDAY, MARCH, 25, 2023

0630-0700h Breakfast – Heritage Hall 
CLL SESSION
0700-0705h Welcome and Introductions – Mt. Temple Ballroom 
0705-0735h Treatment form Newly Diagnosed CLL – Dr. Matthew Davids
0735-0805h Treatment for Relapsed/Refractory CLL – Dr. Constantine Tam
0805-0830h The Value of MRD in Management of CLL in 2023 – Dr. Carolyn Owen
0830-0900h Richter’s Transformation in CLL – Dr. Matthew Davids
0900-1000h Panel Discussion – Chair:  Panel: Dr. Davids, Dr. Tam, Dr. Owen
YOUNG INVESTIGATORS’ POSTER SESSION
1300-1645h Reception – Young Investigators’ Poster and Oral Presentations – Mt Temple Ballroom 
1645-1700h Presentation Best Poster – Dr. Anca Prica
LYMPHOMA SESSION
1700-1705h Welcome and Introductions –  Mt Temple Ballroom 
1705-1730h Best of ASH – Dr. Laurie Sehn
1730-1800h The Promise of Bispecifics in B-cell NHL – Dr. Martin Hutchings
1800-1830h Waldenstroms Macroglobulinemia – Dr. Constantine Tam
1830-1900h Mantle Cell Lymphoma – Dr. Julie Vose
1900h-1925h Panel Discussion – Chair:  Panel: Dr. Hutchings, Dr. Sehn, Dr. Tam, Dr. Vose 
1930h Dinner – Victoria Ballroom 

SUNDAY MARCH 26, 2023

0630-0700h Breakfast – Heritage Hall
LYMPHOMA SESSION
0700-0705h Welcome and Introductions – Mt Temple Ballroom 
0705-0730h Lymphoma Classification Systems: What You Need to Know – Dr. Julie Vose
0730-0800h Relapsed Refractory DLBCL – Dr. Jeremy Abramson
0800-0840h Debate:  What Should be 3rd Line Treatment for DLBCL –
Bispecifics –Dr. Martin Hutchings
CART – Dr. Jeremy Abramson
0840-0905h Maintenance Therapy in B-cell Lymphomas: What to Keep, What to Abandon?- Dr. Diego Villa 
0905h-0955h Panel Discussion: Chair, Panel: Dr. Abramson, Dr. Hutchings, Dr. Vose, Dr. Villa 
0955-1000h Closing Remarks